In silico toxicology protocols

Glenn J. Myatt, Ernst Ahlberg, Yumi Akahori, +80

Regulatory Toxicology and Pharmacology

Toxicology TestingEnvironmental HealthToxicologyBiostatisticsToxicological Aspect +16

Genetic toxicology in silico protocol

Catrin Hasselgren, Ernst Ahlberg, Yumi Akahori, +71

Regulatory Toxicology and Pharmacology

EngineeringGeneticsToxicology TestingRegulatory Safety ScienceToxicology +15

An Evaluation of the Occupational Health Hazards of Peptide Couplers

Jessica Graham, Alejandra Trejo‐Martin, Martyn L. Chilton, +9

Chemical Research in Toxicology

1191 GS-5816, A SECOND GENERATION HCV NS5A INHIBITOR WITH POTENT ANTIVIRAL ACTIVITY, BROAD GENOTYPIC COVERAGE AND A HIGH RESISTANCE BARRIER

Guofeng Cheng, Ming‐Jiun Yu, Betty Peng, +15

Journal of Hepatology

MedicineBroad Genotypic CoverageAntiviral Drug DevelopmentAntiviral TherapyHepatitis +4

Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency

David J. Snodin, Alejandra Trejo‐Martin, David J. Ponting, +13

Chemical Research in Toxicology

Nitrosamine MutagenicityPathologyToxicological MechanismOxidative StressMolecular Pharmacology +15

In silico approaches in carcinogenicity hazard assessment: Current status and future needs

Raymond R. Tice, Arianna Bassan, Alexander Amberg, +38

Computational Toxicology

OncologyPredictive ToxicologySilico ApproachesMedicineChemical Hazard +9

Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines

Alejandra Trejo‐Martin, Joel P. Bercu, Andrew Thresher, +16

Regulatory Toxicology and Pharmacology

PathologyToxicology TestingDrug ResistanceReactive Nitrogen SpecieBioanalysis +19

Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses

Alexander Amberg, Roxanne V. Andaya, Lennart T. Anger, +41

Regulatory Toxicology and Pharmacology

Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®

John O. Link, James G. Taylor, Alejandra Trejo‐Martin, +20

Bioorganic & Medicinal Chemistry Letters

MedicineAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirology +4

Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs)

Joel P. Bercu, Melisa Masuda-Herrera, Alejandra Trejo‐Martin, +17

Regulatory Toxicology and Pharmacology